Nuclear Transport Modifiers for Sepsis Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for microbial inflammation, particularly in cases of sepsis, are inadequate as they fail to effectively inhibit the nuclear transport of signal cascades that lead to host inflammatory responses, causing collateral damage to major organs.
Innovation Solution
Administration of Nuclear Transport Modifiers (NTMs) that target the nuclear import of stress-responsive transcription factors and Sterol Regulatory Element Binding Proteins, such as specific peptides like cSN50.1, to inhibit their nuclear translocation and reduce inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimicrobial therapy is administered to treat microbial infection, then bacterial control is improved, but nuclear transport of signal cascades continues causing inflammatory damage
Solution Approach 1:
The treatment is divided into two separate components: an antimicrobial agent to control bacterial infection and a nuclear transport modifier to block inflammatory signal cascades. This segmentation allows each component to address its specific target independently, resolving the contradiction between bacterial control and inflammatory damage prevention.
Solution Approach 2:
A nuclear transport modifier acts as an intermediary substance that blocks the transport of stress-responsive transcription factors into the nucleus. This intermediary prevents the formation of proinflammatory genes without interfering with antimicrobial therapy, thereby stopping inflammatory damage while maintaining bacterial control.
2Productivity
If host immune response is activated to fight infection, then pathogen clearance is improved, but collateral damage to organs occurs
Solution Approach 1:
The harmful overactive immune response is converted into a beneficial controlled response. The nuclear transport modifier selectively blocks the harmful nuclear transport of proinflammatory signals while allowing the immune system to continue clearing pathogens, thus converting the harmful collateral damage into a beneficial controlled immune response.
Solution Approach 2:
The nuclear transport modifier applies preliminary anti-action by blocking the nuclear transport of stress-responsive transcription factors before they can activate proinflammatory genes. This preliminary block prevents the harmful inflammatory cascade from developing while the immune system continues its pathogen clearance function.
3Object-affected harmful factors
If nuclear transport of transcription factors is inhibited, then inflammatory response is reduced, but pathogen clearance may be affected
Solution Approach 1:
The nuclear transport modifier applies local quality by specifically targeting the nuclear transport of stress-responsive transcription factors involved in proinflammatory gene activation. This localized inhibition affects only the inflammatory pathway while leaving other nuclear transport functions, including those necessary for pathogen clearance, intact.
Solution Approach 2:
The treatment changes the parameter of nuclear transport activity selectively. The nuclear transport modifier alters the transport parameter for stress-responsive transcription factors to block inflammatory signaling, while maintaining normal nuclear transport parameters for other cellular functions including immune response and pathogen clearance.
Data Source
AI summary
Disclosed are compositions and methods for treating microbial inflammation including its end-stage sepsis and conditions associated with the microbial inflammation such as thrombocytopenia and hypoglycogenemia. In one aspect, the compositions and methods disclosed herein can also be used to enhance clearance of microbes from infected tissues, organs, or systems in a subject. Also disclosed herein are compositions and methods for reducing levels of stress responsible transcription factors and metabolic transcription factors in a cell in a subject with microbial inflammation.